Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced a scientific consulting program aimed at optimizing imaging processes and outcomes to accelerate the clinical development of new medical treatments.
“Calyx’s dedicated scientific team has a long history of helping researchers advance their development pipelines and get new treatments to market sooner,” said Gavin Nichols, Chief Executive Officer of Calyx. “Their specific expertise in clinical development makes them a valuable resource to pharmaceutical companies and CROs working to bring new treatments to patients around the world.”
Having supported over 2,600 imaging studies and 250+ new drug approvals, Calyx consultants are routinely engaged by biopharmaceutical researchers to ensure the scientific integrity and regulatory compliance of their imaging processes during clinical development.
Calyx Scientific Consulting delivers a broad range of services to meet the specific needs of new product development, including:
Evaluating whether imaging is required based on specific endpoints
Selecting optimal imaging biomarkers to best demonstrate safety and efficacy at each trial phase
Choosing the ideal image acquisition strategy to best support biomarker requirements
About Calyx
Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market reliably. With deep expertise in clinical development and more than 25 years supporting trial sponsors and clinical research organizations, Calyx harnesses its intelligence and experience to solve complex problems, deliver fast insights, and get new drugs to market every day.
